China
Africa
Explore chapters and articles related to this topic
Current and Future Perspectives of Marine Drugs for Cancer Disorders: A Critical Review
Published in Rohit Dutt, Anil K. Sharma, Raj K. Keservani, Vandana Garg, Promising Drug Molecules of Natural Origin, 2020
Bhaskaran Mahendran, Thirumalaraju Vaishnavi, Vishakante Gowda, Johurul Islam, Narahari Rishitha, Arunachalam Muthuraman, Rajavel Varatharajan
Various marine-derived products are identified as potential therapeutic efficacy in vitro and in vivo. Some of the marine-derived products are under clinical trials use to treat cancer disorders. The ongoing marine drugs in clinical trials are plinabulin, plitidepsin, glembatumumabvedotin, and lurbinectedin at phase III levels; mafodotin, depatuxizumab, polatuzumab vedotin, tisotumab AGS-16C3F, PM184, vedotin, enfortumabvedotin, and monomethyl auristatin F at phase II levels; GSK2857916, ABBV-085, ABBV-399, ABBV-221, ASG-67E, ASG-15ME, bryostatin, marizomib, and SGN-LIV1A at phase I levels (Dyshlovoy and Honecker, 2018; Mayer, 2017; Doronina et al., 2018). Furthermore, the additional marine-derived products are pipelines for the clinical trials. Some of newer molecules are identified in different marine sources. These molecules proved their potency and efficacy in various ailments in laboratory animals. Therefore, marine-derived natural molecules are expected to manage multiple cancer disorders.
The vital role of animal, marine, and microbial natural products against COVID-19
Published in Pharmaceutical Biology, 2022
Aljawharah A. Alqathama, Rizwan Ahmad, Ruba B. Alsaedi, Raghad A. Alghamdi, Ekram H. Abkar, Rola H. Alrehaly, Ashraf N. Abdalla
Plitidepsin (dehydrodidemnin B, 2) is a depsipeptide obtained from the tunicate Aplidium albicans (Milne Edwards, Polyclinidae) and is produced by PharmaMar under the name Aplidin®. It appears to hold greater potential than remdesivir in its activity against SARS-CoV-2, targeting the human protein eEF1A, which is essential for interaction with the N protein during the viral infection (Taglialatela-Scafati 2021). It has shown significant cytotoxic effects on the virus in human cells, with an IC90 of 0.88 nM. It is 27.5 nM more powerful than the remdesivir tested in the same cell line (White et al. 2021). It has been tested in different mouse models where it was initially administered before the mouse was infected with SARS-CoV-2, with the result that it significantly decreased viral load in a similar way to remdesivir. In the second model it suppressed lung inflammation more effectively than did the remdesivir, and this compound is now entering phase III clinical trials to test its effectiveness against COVID-19 (Taglialatela-Scafati 2021).
Influence of protamine shell on nanoemulsions as a carrier for cyclosporine-A skin delivery
Published in Pharmaceutical Development and Technology, 2019
M. Javiera Alvarez-Figueroa, José María Abarca-Riquelme, José Vicente González-Aramundiz
The release of the CsA loaded in the different nanosystems was evaluated upon incubation of highly diluted nanosystems in an acetate buffer (pH 5.5):ethanol (3:2) solution at 37 °C. This buffer allowed us to ensure sink condition throughout the duration of this experiment (24 h). As shown in Figure 4, CsA has a controlled release profile. It is possible to observe that between 10 and 30% of CsA is slowly released within the first 24 h from the different nanosystems. Although no statistically significant differences were observed between the four studied nanosystems, CsA release was slower in nanosystems that had a protamine shell (NC-1P, NC-2P, and NC-i). This could be because protamine plays a role in controlled drug release kinetics. Our results are different from those found in the literature; other polypeptide-based NCs show a pronounced burst effect (near 50–80% in the first hour) when using Plitidepsin or Docetaxel as an active molecule (Lozano et al. 2013; Lollo et al. 2015). Moreover, a recent study demonstrated that PLGA nanoparticles show a burst CsA release profile, which was pH dependent. In this study, about 70% of CsA was released in the first 6 h at pH 1.2 and 6.8 (Naeem et al. 2018). Our systems have more control of the release of this drug and do not present a burst effect.
Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy
Published in Artificial Cells, Nanomedicine, and Biotechnology, 2018
Md. Habban Akhter, Nv Sateesh Madhav, Javed Ahmad
Goñi-de-Cerio et al. [19] synthesized polypeptide-based copolymers such as poly (trimethylene carbonate)-bock-poly(L-glutamic acid) and encapsulated plitidepsin for targeting potential to EGFR with regard to HT29 and LS174T colorectal cancer cell lines. The cytotoxicity profile indicated excellent biocompatibility and cellular uptake of EGFR targeted and plitidepsin loaded polymersome indicated that colorectal cancer cell lines were more sensitive to anti-EGFR-drug-loaded than non-targeted drug-loaded polymersomes [19].